According to the latest report by IMARC Group, titled “United States Hospital Acquired Disease Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the United States hospital acquired disease testing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026. 

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request Free Report Sample: https://www.imarcgroup.com/united-states-hospital-acquired-disease-testing-market/requestsample

Hospital-acquired diseases or infections (HAIs) are nosocomially acquired from the surroundings of clinics, hospitals, rehabilitation centers, and nursing homes. HAIs can be differentiated into endogenic and exogenic infections. Some of the frequently contracted nosocomial infections include urinary tract, surgical wounds, and lower respiratory tract infections. These diseases mostly occur due to the improper maintenance of hygiene within a healthcare setup, such as emergency rooms (ERs) and intensive care units (ICU).

Checkout- https://www.imarcgroup.com/checkout?id=2986&method=1

The United States hospital-acquired disease testing market growth is primarily being influenced by the introduction of stringent regulations by the Government for ensuring proper hygiene across clinics, hospitals and other healthcare facilities. Other than this, increasing awareness amongst patients regarding the benefits of the early detection of HAIs is creating a positive outlook for the market. Other factors, such as a rapid rise in the geriatric population, which is more prone to HAIs, and the expansion in the medical tourism sector, are supporting the market growth.

United States Hospital Acquired Disease Testing Market 2021-2026 Competitive Analysis and Segmentation:

Competitive Landscape with Key Players:

The competitive landscape of the united states hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.

Key Market Segmentation:

The report has segmented the united states hospital acquired disease testing market on the basis of indication and region.

Breakup by Indication:

• UTI (Urinary Tract Infection)
• SSI (Surgical Site Infection)
• Pneumonia
• Bloodstream Infections
• MRSA (Methicillin-Resistant Staphylococcus Aureus)
• Others

Breakup by Region:

• Northeast
• Midwest
• South
• West

Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/united-states-hospital-acquired-disease-testing-market

Key highlights of the report:            

• Market Performance (2015-2020)
• Market Outlook (2021-2026)
• Industry Trends
• Market Drivers and Success Factors
• The Impact of COVID-19 on the Global Market
• Value Chain Analysis
• Structure of the Global Market
• Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us                              

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group

30 N Gould St Ste R

Sheridan, WY 82801 USA – Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800